HDAC Inhibition to Prime Immune Checkpoint Inhibitors.
HDAC Inhibition to Prime Immune Checkpoint Inhibitors.
复制标题
DOI：
10.3390/cancers14010066
复制
发表时间：
2021-12-23
期刊：
影响因子：
5.2
通讯作者：
Le Tourneau C
中科院分区：
文献类型：
--
作者：
Borcoman E;Kamal M;Marret G;Dupain C;Castel-Ajgal Z;Le Tourneau C
免疫治疗在医学肿瘤学方面取得了突破，几种免疫检查点抑制剂被批准用于多种癌症类型。由于只有少数患者对这些药物有持久的反应，因此开发了联合策略和新型免疫治疗药物以进一步抵消肿瘤免疫逃逸。表观遗传调节可以在肿瘤发生中改变，有利于肿瘤进展。药物的开发已经成功地靶向了淋巴瘤和白血病患者的这些改变的表观遗传模式。最近的研究表明，表观遗传学改变也可以在肿瘤免疫逃逸中发挥关键作用。与HDAC抑制剂一样，表药可以引发抗肿瘤免疫应答，因此构成了开发与免疫治疗剂的组合策略的有趣伙伴。随着多个免疫检查点抑制剂在临床常规中获批，免疫治疗在医学肿瘤学领域取得了突破性进展，改善了难治性疾病晚期癌症患者的总生存期。然而，只有少数患者经历了这些药物的持久反应，这导致了联合策略和新型免疫治疗药物的开发，以进一步抵消肿瘤免疫逃逸。表观遗传调节可以在肿瘤发生中改变，有利于肿瘤进展。药物的开发使得成功靶向淋巴瘤和白血病患者的这些改变的表观遗传模式成为可能。最近的研究表明，表观遗传学改变也可以在肿瘤免疫逃逸中发挥关键作用。与HDAC抑制剂一样，表药可以引发抗肿瘤免疫应答，因此构成了开发与免疫治疗剂的组合策略的有趣伙伴。在这篇综述中，我们将讨论参与肿瘤发生和免疫逃逸的表观遗传调控，并描述HDAC抑制剂与免疫治疗相结合的临床发展。
Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in multiple cancer types. Since only a minority of patients experience a durable response with these agents, combination strategies and novel immunotherapy drugs were developed to further counteract tumor immune escape. Epigenetic regulations can be altered in oncogenesis, favoring tumor progression. The development of epidrugs has allowed for successfully targeting these altered epigenetic patterns in lymphoma and leukemia patients. It has been recently shown that epigenetic alterations can also play a key role in tumor immune escape. Epidrugs, like HDAC inhibitors, can prime the anti-tumor immune response, therefore constituting interesting partners to develop combination strategies with immunotherapy agents. Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in clinical routine, improving overall survival of advanced cancer patients with refractory disease. However only a minority of patients experience a durable response with these agents, which has led to the development of combination strategies and novel immunotherapy drugs to further counteract tumor immune escape. Epigenetic regulations can be altered in oncogenesis, favoring tumor progression. The development of epidrugs has allowed targeting successfully these altered epigenetic patterns in lymphoma and leukemia patients. It has been recently shown that epigenetic alterations can also play a key role in tumor immune escape. Epidrugs, like HDAC inhibitors, can prime the anti-tumor immune response, therefore constituting interesting partners to develop combination strategies with immunotherapy agents. In this review, we will discuss epigenetic regulations involved in oncogenesis and immune escape and describe the clinical development of combining HDAC inhibitors with immunotherapies.
登录
查看更多内容
DOI：
10.1038/s41580-020-0262-8
发表时间：
2020-09
期刊：
Nature reviews. Molecular cell biology
影响因子：
--
作者：
Martire S;Banaszynski LA
通讯作者：
Banaszynski LA
将免疫疗法与表皮药物相结合治疗不同部位的鳞状细胞癌：PEVO 篮子试验的基本原理和设计。
影响因子：
7.3
作者：
de Guillebon E;Jimenez M;Mazzarella L;Betsou F;Stadler P;Peták I;Jeannot E;Chanas L;Servant N;Marret G;Duso BA;Legrand F;Kornerup KN;Bernhart SH;Balogh G;Dóczi R;Filotás P;Curigliano G;Bièche I;Guérin J;Dirner A;Neuzillet C;Girard N;Borcoman E;Larbi Chérif L;Tresca P;Roufai DB;Dupain C;Scholl S;André F;Fernandez X;Filleron T;Kamal M;Le Tourneau C
通讯作者：
Le Tourneau C
影响因子：
50.3
作者：
Figueroa ME;Abdel-Wahab O;Lu C;Ward PS;Patel J;Shih A;Li Y;Bhagwat N;Vasanthakumar A;Fernandez HF;Tallman MS;Sun Z;Wolniak K;Peeters JK;Liu W;Choe SE;Fantin VR;Paietta E;Löwenberg B;Licht JD;Godley LA;Delwel R;Valk PJ;Thompson CB;Levine RL;Melnick A
通讯作者：
Melnick A
影响因子：
45.3
作者：
Luebbert, Michael;Suciu, Stefan;Wijermans, Pierre W.
通讯作者：
Wijermans, Pierre W.
影响因子：
11.2
作者：
Lai, Cheng-Jung;Bao, Rudi;Qian, Changgeng
通讯作者：
Qian, Changgeng